1Baxter EJ, Scott LM, Campbell PJ, et al. Acqurired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorder [J]. Lancet, 2005, 365(9464) :1054 - 1061.
2Campbell PJ, Linda MS, Georgina B, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study [ J]. Lancet, 2005, 366(9501 ) :1945 - 1953.
3Anthony JB, Heike LP. Chromosome abnormalities and molecular markers in myeloprolificative disorders [ J ]. Semin Hematol, 2005, 42(4) :196-205.
5LEVINE R L, WADLEIGH M, COOLS J, et al. Activating mutation in the tyrosinekinase JAK2 in polycythemia vera, essential thrombocythemia,and myeloid metaplasia with myelofibrosis[ J]. Cancert Cell,2005,7:387 -397.
6MIURA O, NAKAMURA N, QUELLE F W, et al. Erythro protein association of the JAK2 protein tyrosine kinase with the erythro protein receptor in vivo[J]. Blood,1994,84(5) :1501 - 1507.
7WATANABE S, LTOH T, ARAI K. JAK2 is essential for activation of c-fos and cmyc promoters and cell proliferation through the human granulocyte2macrophage colony-stimulating factor receptor in BA/F3 cells [ J ] . J. Biol. Chem. ,1996,271: 12681 - 12686.
8SAHARINEN P,TAKALUOMA K, SILVENNOINEC O. Regulation of the JAK2 tyrosine kinase by its pseudokinase domain [J]. Mol. Cell. Biol. ,2000(20) :3387 -3395.
9FERRAND A,KOWALSKI-CHAUVEL A,BERTRAND C, et al. Involvement of JAK2 upstream of the PI 3-kinase in cell - cell adhesion regulation by gastrin[J]. Exp. Cell. Res,2004,301 (2) :128 -138.
10NAKAJIMA H,TAKENAKA M, KAIMORI J Y, et al. Activation of the signal transducer and activator of transcription signaling pathway in renal proximal tubular cells by albumin[J]. J. Am. Soc. Nephrol. , 2004,15(2) :276 - 285.
